Jacobo Mintzer to Psychotic Disorders
This is a "connection" page, showing publications Jacobo Mintzer has written about Psychotic Disorders.
Connection Strength
1.857
-
Using risperidone for Alzheimer's dementia-associated psychosis. Expert Opin Pharmacother. 2008 Oct; 9(14):2537-43.
Score: 0.283
-
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008; 28(5):291-303.
Score: 0.269
-
The many faces of psychosis in the elderly. Curr Opin Psychiatry. 2007 Nov; 20(6):551-8.
Score: 0.266
-
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov; 15(11):918-31.
Score: 0.266
-
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91.
Score: 0.236
-
Psychosis in elderly patients: classification and pharmacotherapy. J Geriatr Psychiatry Neurol. 2003 Dec; 16(4):199-206.
Score: 0.202
-
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012 Oct 18; 367(16):1497-507.
Score: 0.094
-
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May; 22(5):475-84.
Score: 0.064
-
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep; 14(9):767-76.
Score: 0.061
-
A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Curr Med Res Opin. 2004 Sep; 20(9):1483-91.
Score: 0.053
-
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase. 2001; 7(2):105-10.
Score: 0.041
-
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry. 2012 Apr; 20(4):362-73.
Score: 0.023